Eton Pharmaceuticals (ETON) investor relations material

Strategic vision and portfolio growth

• Focused on building the largest rare disease portfolio in the U.S., targeting ultra-rare diseases with patient populations under 20,000.

• Aims to have 100 products on the market within 10 years, expanding across all therapeutic areas including hematology, endocrinology, metabolic disorders, nephrology, and hepatology.

• Currently has 11 products, with two more launches expected this year and several more next year, surpassing 15 products soon.

• Growth driven by organic product expansion, internal development, and strategic acquisitions/licensing.

• Plans to reach $500+ million in peak sales by 2030, with a disciplined approach to both small and large acquisitions.

Commercial performance and financial outlook

• Expects sales to exceed $120 million in 2026 and reach a $200 million annual run rate by the end of 2027.

• EBITDA margins projected to surpass 30% in 2026 and 50% by 2028.

• Each product is profitable and managed as an individual business, leveraging a concentrated prescriber base for efficient commercialization.

• INCRELEX, ALKINDI SPRINKLE, KHINDIVI, and HEMANGEOL are key growth drivers, with label expansions and new indications planned.

• Margin expansion is supported by both internal pipeline growth and accretive acquisitions.

Patient-centric programs and advocacy

• Eton Cares program ensures zero copay for eligible patients, removing access barriers and expediting product delivery.

• Strong collaboration with patient advocacy groups to increase awareness and support, including events like Camp Cortisol.

• Commercial strategy leverages small, specialized sales teams targeting centers of excellence for rare diseases.

• Focus on direct patient engagement to address gaps in physician communication.

• U.S.-centric approach with international distribution via partners or special access programs.